Skip to main
AXGN

AxoGen (AXGN) Stock Forecast & Price Target

AxoGen (AXGN) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Axogen is a promising company with a strong revenue growth, higher gross margin, and increasing profitability. With potential expansion in new segments and positive financials, the company has a positive outlook for the future. However, the company may face risks such as market penetration and commoditization. Overall, AXGN has a solid product portfolio and a presence in the prostate market, with potential for further growth and expansion after the completion of their clinical trials.

Bears say

Axogen is a company that has a strong focus on the extremities market and its portfolio of nerve repair products. However, the company's financials, including its EV/EBITDA and P/E ratios, show that it is currently overvalued compared to its peers. While the company has potential for growth with its products and partnerships, it still faces challenges in terms of market development and clinical efforts, and the lack of reimbursement for its nerve repair devices. Additionally, there is a lack of evidence in the Urology market, where the company is trying to expand, and the executive compensation structure raises potential concerns about alignment with shareholder interests. Overall, these factors contribute to a negative outlook on the company's stock.

AxoGen (AXGN) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AxoGen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AxoGen (AXGN) Forecast

Analysts have given AxoGen (AXGN) a Strong Buy based on their latest research and market trends.

According to 9 analysts, AxoGen (AXGN) has a Strong Buy consensus rating as of Sep 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AxoGen (AXGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.